Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miconazole SCHEMBL2866 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL13934598 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| (R)-Miconazole SCHEMBL2867 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL7647866 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL9662051 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| (R)-Miconazole SCHEMBL30594078 | 1.00 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL9479808 | 0.99 | IDO1 (0.98) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL9479815 | 0.99 | IDO1 (0.98) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| (R)-Miconazole SCHEMBL3367 | 0.99 | IDO1 (0.98) | IDO1CYP2C9CYP3A4LMNACYP1A2 | |
| Miconazole SCHEMBL10575722 | 0.99 | IDO1 (0.98) | IDO1CYP2C9CYP3A4LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-3946323-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2022-02-09 | — | — | EP | claimed |
| WO-2020201378-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE COMPRISING AT LEAST ONE AZOLATED LOCAL ANTIFUNGAL SUBSTANCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2020-10-08 | — | — | WO | claimed |
| US-20250352526-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12329751-B2 | Topical roflumilast formulation having antifungal properties | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| EP-4255393-B1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | ARCUTIS BIOTHERAPEUTICS INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12272440-B2 | Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns | I.D. THERAPEUTICS LLC (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090508-A1 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250090509-A1 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| EP-0382777-A1 | AQUEOUS PREPARATION OF LIPOSOME COMPOSITION. | LIPOSOME CO INC (US) | 1990-08-22 | — | — | EP | disclosed |
| WO-1989003679-A1 | AQUEOUS PREPARATION OF LIPOSOME COMPOSITION | THE LIPOSOME COMPANY, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| US-4735967-A | ADMINISTERING SALTS OF SHORT CHAIN FATTY ACIDS | NEESBY TORBEN E (US) | 1988-04-05 | — | — | US | disclosed |
| US-4603122-A | 2-DEOXY-D-GLUCOSE | BLOUGH HERBERT A | 1986-07-29 | — | — | US | disclosed |
| US-4542020-A | CELLULOSE DERIVATIVE HYDROCOLLOID, LOW MELTING BASE | E. R. SQUIBB & SONS, INC. (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0041795-B1 | INJECTABLE COMPOSITION OF RAPAMYCIN | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-01-16 | — | — | EP | disclosed |
| US-4315001-A | VINSION DEFECTS; UROGENITAL DISEASES | BLOUGH HERBERT A | 1982-02-09 | — | — | US | disclosed |
| EP-0041795-A2 | Injectable composition of rapamycin | AYERST, MCKENNA AND HARRISON INC. (CA) | 1981-12-16 | — | — | EP | disclosed |
| US-4039677-A | FUNGICIDES, BACTERICIDES, ANTIPROTOZOA AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329751-B2 | Topical roflumilast formulation having antifungal properties | PADI4, PIK3C3, PADI1 | IDO1 882/4885CYP2C9 1604/4885CYP3A4 125/4885 |
| US-20250090508-A1 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | TSLP, MMP11, MMP13 | IDO1 578/4885CYP2C9 1149/4885CYP3A4 1532/4885 |
| US-20250090509-A1 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | TSLP, MMP11, MMP13 | IDO1 578/4885CYP2C9 1149/4885CYP3A4 1532/4885 |
| US-20250352526-A1 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | PADI4, PIK3C3, PADI1 | IDO1 882/4885CYP2C9 1604/4885CYP3A4 125/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | IDO1 286/4885CYP2C9 2205/4885CYP3A4 2163/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | IDO1 3554/4885CYP2C9 3805/4885CYP3A4 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.